Gallacher Capital Management LLC Buys 1,192 Shares of Genmab A/S (NASDAQ:GMAB)

Gallacher Capital Management LLC increased its stake in shares of Genmab A/S (NASDAQ:GMAB) by 17.9% during the 1st quarter, HoldingsChannel.com reports. The fund owned 7,865 shares of the company’s stock after acquiring an additional 1,192 shares during the period. Gallacher Capital Management LLC’s holdings in Genmab A/S were worth $235,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Grandfield & Dodd LLC raised its holdings in Genmab A/S by 3.4% during the first quarter. Grandfield & Dodd LLC now owns 26,418 shares of the company’s stock worth $790,000 after acquiring an additional 860 shares in the last quarter. Thompson Davis & CO. Inc. bought a new stake in Genmab A/S in the first quarter valued at approximately $202,000. Capstone Investment Advisors LLC bought a new stake in Genmab A/S in the first quarter valued at approximately $655,000. Janney Montgomery Scott LLC raised its stake in Genmab A/S by 43.2% in the first quarter. Janney Montgomery Scott LLC now owns 17,369 shares of the company’s stock valued at $520,000 after buying an additional 5,238 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new stake in Genmab A/S in the first quarter valued at approximately $43,000. Institutional investors own 7.07% of the company’s stock.

Analyst Ratings Changes

GMAB has been the topic of several research analyst reports. Morgan Stanley restated an “underweight” rating on shares of Genmab A/S in a research note on Tuesday, March 26th. BTIG Research upped their price objective on Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, June 27th. Finally, Truist Financial increased their target price on Genmab A/S from $50.00 to $53.00 and gave the stock a “buy” rating in a research note on Tuesday, June 4th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Genmab A/S currently has an average rating of “Hold” and a consensus price target of $49.50.

Genmab A/S Price Performance

NASDAQ:GMAB traded up $0.73 during trading hours on Friday, reaching $26.97. 218,126 shares of the company were exchanged, compared to its average volume of 554,367. The company has a market capitalization of $17.84 billion, a P/E ratio of 21.87, a P/E/G ratio of 0.94 and a beta of 0.97. Genmab A/S has a 1-year low of $24.53 and a 1-year high of $42.72. The business has a 50 day moving average of $27.44 and a 200 day moving average of $28.76.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $0.16 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.16. The business had revenue of $603.30 million for the quarter, compared to the consensus estimate of $594.23 million. Genmab A/S had a return on equity of 18.90% and a net margin of 30.74%. As a group, equities research analysts anticipate that Genmab A/S will post 1.11 earnings per share for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.